

29 October 2014

Company Announcements Office
Australian Securities Exchange

**New NHS Wales guidelines position automated,
validated decontamination systems as the optimal solution for
ultrasound probe decontamination**

The NHS Wales recently released new section, part C of the WHTM 01.06 series guidelines for the decontamination of flexible endoscopes including guidance on non-channelled endoscopes and ultrasound probes. Attention in the guidelines is drawn to the MHRA Medical Device Alert (2012/037) dealing with reusable transoesophageal echocardiography, transvaginal and transrectal ultrasound probes where the death of a patient from Hepatitis B infection may have been associated with the failure to appropriately decontaminate a probe.

The new part C stresses the need for automated, validated decontamination systems as the "optimum decontamination process" and picture the trophon® EPR as an example of such. The document also recommends that, where appropriate, methods are in place to manage the process of cleaning and disinfection of ultrasound probes in the location they are being used. The trophon EPR is designed to be used as a point of care solution.

"These new guidelines reflect the importance of proper decontamination of ultrasound probes to mitigate serious risks," said Michael Kavanagh, CEO and President. The trophon EPR meets the necessary requirements outlined in the guidelines such as validation, evidence of efficacy for high level disinfection, compatibility with the ultrasound probes as approved by the probe OEMs, ability to be used at point of care, a traceability solution and importantly automation for the optimal process."

"The new guidelines present the opportunity for trophon to become the new standard of care for ultrasound probe decontamination," said Stuart Mills, UK Toshiba Ultrasound Sales Director. There are a number of hospitals in Wales who have already adopted the trophon as an automated optimal solution and these guidelines now support further growth in Wales.

Further information on the guidelines can be found on the NHS Wales site referencing WHTM 01-06: Decontamination of flexible endoscopes Part C: Operational management (including guidance on non-channelled endoscopes and ultrasound probes) 2014. The NHS Wales does not endorse or promote any specific commercial products.

Michael Kavanagh
CEO / President



For more information please contact:

Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600

Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722

Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722.

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit www.nanosonics.com.au